Sort   by:  
 Page size 
UnknownVariability in the Log Domain and Limitations to Its Approximation by the Normal Distribution.
Not available
S-EPMC7239339 | biostudies-literature
UnknownDrug Distribution in Brain and Cerebrospinal Fluids in Relation to IC50 Values in Aging and Alzheimer's Disease, Using the Physiologically Based LeiCNS-PK3.0 Model.
Not available
S-EPMC9246802 | biostudies-literature
UnknownLumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.
Not available
S-EPMC8405486 | biostudies-literature
UnknownThe PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells
Not available
S-EPMC9710098 | biostudies-literature
UnknownTranslational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.
Not available
S-EPMC5270293 | biostudies-literature
UnknownUsing Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.
Not available
S-EPMC5270295 | biostudies-literature
UnknownModel-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Not available
S-EPMC5270291 | biostudies-literature
UnknownPembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.
Not available
S-EPMC5270292 | biostudies-literature
UnknownCrowdsourced Asparagus Urinary Odor Population Kinetics.
Not available
S-EPMC5784735 | biostudies-literature
UnknownPopulation Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Not available
S-EPMC5270297 | biostudies-literature
Sort   by:  
 Page size